This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chronos, N. A. Articles by Buller, N. P. Search for Related Content PubMed PubMed Citation Articles by Chronos, N. A. Articles by Buller, N. P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty

Circulation, Vol 88, 2035-2044, Copyright © 1993 by American Heart Association

ARTICLES

Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology

NA Chronos, AH Goodall, DJ Wilson, U Sigwart and NP Buller
Department of Invasive Cardiology, Royal Brompton National Heart and Lung Hospital, London.

BACKGROUND. Thrombotic complications occurring during coronary angiography and percutaneous transluminal coronary angioplasty (PTCA) are relatively frequent and can be influenced by the type of radiographic contrast media used. Low osmolar contrast media (LOCM), both ionic and nonionic, have been considered to be safer than the older high osmolar contrast media (HOCM), causing less haemodynamic and symptomatic side effects. Recently, however, nonionic LOCM have been associated with an increased incidence of thrombotic events, including coronary occlusion and stroke. METHODS AND RESULTS. The effects of commonly used contrast media on platelets in native blood were investigated using immunolabeling and flow cytometry to detect platelet activation in vitro. A nonionic LOCM (Omnipaque) caused profound platelet degranulation in nearly 80% of platelets compared with 2 to 3% of platelets in the control. Conversely, an ionic HOCM (Urografin) caused only 25% degranulation, whereas an ionic LOCM (Hexabrix) caused no platelet activation and, furthermore, it inhibited the effects of thrombin on platelets. Platelet degranulation, quantified by immunolabeling, was paralleled by release of beta-thromboglobulin and platelet factor 4 from platelet alpha-granules. Blood from patients anticoagulated with heparin and pretreated with standard-dose aspirin in preparation for PTCA showed the same pattern of contrast media- induced platelet activation as normal subjects. CONCLUSIONS. These results suggest that the type of contrast media used during invasive imaging of the vasculature could have a significant effect on platelets. Platelet degranulation within a PTCA-damaged vessel would be increased by a nonionic contrast medium, releasing procoagulant molecules and platelet-derived growth factors into the damaged vessel lumen, which might contribute to acute thrombosis and the initiation of the restenosis process.

This article has been cited by other articles:

				R. Jaumdally, C. Varma, R. J. Macfadyen, and G. Y.H. Lip Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment? Eur. Heart J., April 2, 2007; 28(8): 929 - 940. [Abstract] [Full Text] [PDF]

				Y. Ramot and A. Nyska Drug-Induced Thrombosis--Experimental, Clinical, and Mechanistic Considerations Toxicol Pathol, February 1, 2007; 35(2): 208 - 225. [Abstract] [Full Text] [PDF]

				C. Mueller, G. Buerkle, H. J. Buettner, J. Petersen, A. P. Perruchoud, U. Eriksson, S. Marsch, and H. Roskamm Prevention of Contrast Media-Associated Nephropathy: Randomized Comparison of 2 Hydration Regimens in 1620 Patients Undergoing Coronary Angioplasty Arch Intern Med, February 11, 2002; 162(3): 329 - 336. [Abstract] [Full Text] [PDF]

				B. Scheller A reply Eur. Heart J., January 2, 2002; 23(2): 173 - 175. [Full Text] [PDF]

				W.B. Batchelor From COURT to HOMBURG: in search of the optimal contrast agent Eur. Heart J., November 1, 2001; 22(21): 2026 - 2028. [PDF]

				A D Blann, R Adams, R Ashleigh, S Naser, U Kirkpatrick, and C N McCollum Changes in endothelial, leucocyte and platelet markers following contrast medium injection during angiography in patients with peripheral artery disease Br. J. Radiol., September 1, 2001; 74(885): 811 - 817. [Abstract] [Full Text] [PDF]

				V. Legrand Ionic or non-ionic contrast during coronary intervention: does it make a difference? Eur. Heart J., March 1, 2001; 22(5): 353 - 354. [PDF]

				B Scheller, B Hennen, A Pohl, H Schieffer, and T Markwirth Acute and subacute stent occlusion; risk-reduction by ionic contrast media Eur. Heart J., March 1, 2001; 22(5): 385 - 391. [Abstract] [PDF]

				B. Chandrasekar and J.-F. Tanguay Platelets and restenosis J. Am. Coll. Cardiol., March 1, 2000; 35(3): 555 - 562. [Abstract] [Full Text] [PDF]

				M. E. Bertrand, E. Esplugas, J. Piessens, and W. Rasch Influence of a Nonionic, Iso-Osmolar Contrast Medium (Iodixanol) Versus an Ionic, Low-Osmolar Contrast Medium (Ioxaglate) on Major Adverse Cardiac Events in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty : A Multicenter, Randomized, Double-Blind Study Circulation, January 18, 2000; 101(2): 131 - 136. [Abstract] [Full Text] [PDF]

				R. Schrader, I. Esch, R. Ensslen, W. A. Fach, H. Merle, D. Scherer, H. Sievert, H. F. Spies, and H. E. Zeplin A randomized trial comparing the impact of a nonionic (iomeprol) versus an ionic (ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty J. Am. Coll. Cardiol., February 1, 1999; 33(2): 395 - 402. [Abstract] [Full Text] [PDF]

				M. Gawaz, F.-J. Neumann, and A. Schomig Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy Circulation, January 12, 1999; 99 (1): e1 - e11. [Full Text] [PDF]

				S. Pislaru, C. Pislaru, M. Szilard, J. Arnout, and F. Van de Werf In vivo effects of contrast media on coronary thrombolysis J. Am. Coll. Cardiol., October 1, 1998; 32(4): 1102 - 1108. [Abstract] [Full Text] [PDF]